Drugs / Pegalyted interferon
Pegalyted interferon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01589952 | Mar 2012 → Feb 2013 | chronic hepatitis B virus infection | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
Press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Gilead Sciences | Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗ |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon vrtx.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegalyted interferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01589952 ↗ |
| Known as | Peg-IFN | “According to published literature, treatment with pegylated interferon (Peg-IFN) is associated with end of treatment response in treatment naive patients with chronic hepatitis B (CHB).” NCT01589952 ↗ |
| Known as | Pegylated interferon | “According to published literature, treatment with pegylated interferon (Peg-IFN) is associated with end of treatment response in treatment naive patients with chronic hepatitis B (CHB).” NCT01589952 ↗ |
| Route | Subcutaneous | “Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks” NCT01589952 ↗ |